Lundin Law PC announces a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. concerning possible violations of federal securities laws between March 5, 2015 and September 8, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the March 28, 2016, lead plaintiff motion deadline.
According to the complaint, the company issued materially false and misleading statements to investors regarding the efficacy and safety of Eravacycline, and its capacity for approval by both the FDA and the European Medicines Agency (EMA).
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
